These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 18393917

  • 21. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
    Mittman N, Desiraju B, Meyer KB, Chattopadhyay J, Avram MM.
    Kidney Int Suppl; 2010 Aug; (117):S33-6. PubMed ID: 20671742
    [Abstract] [Full Text] [Related]

  • 22. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
    Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG, Medical Directors of Dialysis Clinic Inc.
    Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
    [Abstract] [Full Text] [Related]

  • 23. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
    Dyer CA.
    Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
    [Abstract] [Full Text] [Related]

  • 24. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M.
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [Abstract] [Full Text] [Related]

  • 25. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.
    Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G.
    Pediatr Nephrol; 2006 Oct; 21(10):1434-9. PubMed ID: 16900383
    [Abstract] [Full Text] [Related]

  • 26. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
    Matuszkiewicz-Rowińska J, Żebrowski P.
    Wiad Lek; 2016 Oct; 69(5):756-759. PubMed ID: 28033603
    [Abstract] [Full Text] [Related]

  • 27. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
    Joist HE, Ahya SN, Giles K, Norwood K, Slatopolsky E, Coyne DW.
    Clin Nephrol; 2006 May; 65(5):335-41. PubMed ID: 16724654
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.
    Ren Fail; 2012 May; 34(3):297-303. PubMed ID: 22251408
    [Abstract] [Full Text] [Related]

  • 29. [Cholecalciferol supplementation improves secondary hyperparathyroidism control in hemodialysis patients].
    Massimetti C, Bellasi A, Feriozzi S.
    G Ital Nefrol; 2020 Jun 10; 37(3):. PubMed ID: 32530156
    [Abstract] [Full Text] [Related]

  • 30. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
    Brancaccio D, Bommer J, Coyne D.
    Drugs; 2007 Jun 10; 67(14):1981-98. PubMed ID: 17883283
    [Abstract] [Full Text] [Related]

  • 31. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.
    Nefrologia; 2015 Jun 10; 35(4):363-73. PubMed ID: 26306956
    [Abstract] [Full Text] [Related]

  • 32. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
    Koc H, Hoser H, Akdag Y, Kendir C, Ersoy FF.
    Int Urol Nephrol; 2019 Jul 10; 51(7):1261-1270. PubMed ID: 31161518
    [Abstract] [Full Text] [Related]

  • 33. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM.
    Clin Ther; 1999 Mar 10; 21(3):432-41. PubMed ID: 10321413
    [Abstract] [Full Text] [Related]

  • 34. Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients.
    Zheng JQ, Hou YC, Zheng CM, Lu CL, Liu WC, Wu CC, Huang MT, Lin YF, Lu KC.
    Nutrients; 2016 Nov 05; 8(11):. PubMed ID: 27827962
    [Abstract] [Full Text] [Related]

  • 35. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D.
    Kidney Int; 2003 Apr 05; 63(4):1483-90. PubMed ID: 12631365
    [Abstract] [Full Text] [Related]

  • 36. Spotlight on paricalcitol in secondary hyperparathyroidism.
    Robinson DM, Scott LJ.
    Treat Endocrinol; 2005 Apr 05; 4(3):185-6. PubMed ID: 15898824
    [Abstract] [Full Text] [Related]

  • 37. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
    Akiba T.
    Clin Calcium; 2007 May 05; 17(5):767-71. PubMed ID: 17471008
    [Abstract] [Full Text] [Related]

  • 38. Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease.
    Han T, Rong G, Quan D, Shu Y, Liang Z, She N, Liu M, Yang B, Cheng G, Lv Y, Stern L.
    Biomed Res Int; 2013 May 05; 2013():320560. PubMed ID: 23509710
    [Abstract] [Full Text] [Related]

  • 39. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
    Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J.
    Am J Kidney Dis; 1998 Oct 05; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
    [Abstract] [Full Text] [Related]

  • 40. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Cai P, Tang X, Qin W, Ji L, Li Z.
    Int Urol Nephrol; 2016 Apr 05; 48(4):571-84. PubMed ID: 26748501
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.